<DOC>
	<DOCNO>NCT00096941</DOCNO>
	<brief_summary>This multicenter , open label extension study . Subjects complete treatment parent study pertuzumab , either alone combination agent , receive least one dose pertuzumab parent study eligible inclusion trial continue receive clinical benefit .</brief_summary>
	<brief_title>A Study Evaluate Subjects Treated With rhuMab 2C4 ( Pertuzumab ) Previous Genentech Phase II Cancer Study</brief_title>
	<detailed_description />
	<mesh_term>Pertuzumab</mesh_term>
	<criteria>Signed informed consent ECOG performance status 0 , 1 , 2 Completion treatment previous Genentech sponsor , Phase II cancer study pertuzumab , either alone combination agent , least one dose pertuzumab receive parent study Less 3 month since last dose pertuzumab parent study Use effective mean contraception men woman childbearing potential Granulocyte count &gt; = 1500/uL Platelet count &gt; = 75,000/uL Hemoglobin &gt; = 9 g/dL ( hemoglobin may support transfusion erythropoietin approve hematopoietic growth factor ; darbepoetin [ Aranesp ( R ) ] permit ) Serum bilirubin less equal upper limit normal ( ULN ) ( unless due Gilbert 's disease ) Alkaline phosphatase , AST , ALT &lt; = 2.5x ULN ( &lt; = 5x ULN subject liver metastasis ; alkaline phosphatase upper limit subject bone metastasis ) Serum creatinine &lt; = 1.5x ULN International normalize ratio ( INR ) &lt; 1.5 activate partial thromboplastin time ( aPTT ) &lt; 1.5x ULN ( except subject receive warfarin ) Recent ( within last 3 month ) , current , planned participation experimental drug study Genentechsponsored pertuzumab cancer study Any unresolved irreversible NCICTC Grade 3 4 adverse event clinically meaningful cardiac adverse event ( grade ) pertuzumabrelated ongoing parent study Recent ( within last 3 month ) current treatment HER pathway inhibitor pertuzumab ( e.g. , Herceptin ( R ) [ Trastuzumab ] , Iressa &lt; TM &gt; [ gefitinib ] , Tarceva &lt; TM &gt; [ erlotinib hydrochloride ] , C225 , CI1033 , TAK165 ) monoclonal antibody Clinical evidence central nervous system brain metastasis Ejection fraction â‰¤50 % , determine ECHO ( MUGA ) Uncontrolled hypercalcemia ( &gt; 11.5 mg/dL ) Recent anthracycline exposure ( within last 3 month ) cumulative exposure &gt; 360 mg/m^2 doxorubicin equivalent ( i.e. , liposomal doxorubicin , &gt; 120 mg/m^2 mitoxantrone , &gt; 90 mg/m^2 idarubicin ) Ongoing corticosteroid use ( except subject stable dos &lt; 20 mg prednisone daily [ equivalent ] take corticosteroid reason cancer ) Other malignancy ( except adequately treat carcinoma situ cervix , ductal carcinoma situ breast , basal squamous cell skin cancer ) Serious systemic disease , include active infection , uncontrolled hypertension ( diastolic blood pressure &gt; 100 mmHg two consecutive occasion ) , unstable angina , congestive heart failure , myocardial infarction unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia [ i.e. , atrial fibrillation ] , paroxysmal supraventricular tachycardia , control hypertension eligible ) Liver disease ( include viral hepatitis ) , current alcohol abuse , cirrhosis Known human immunodeficiency virus infection Pregnancy lactation Major surgery significant traumatic injury within 3 week prior Day 1 Inability comply study followup procedure Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicates continue use investigational drug may render subject high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Advanced solid cancer</keyword>
	<keyword>HER2</keyword>
	<keyword>EGFR</keyword>
</DOC>